Company: INSP
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001609550-25-000032
Chunk: 17

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 Ended June 30, 2024Common StockSharesAmountAdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncome (Loss)AccumulatedDeficitTotalStockholders'EquityBalance at December 31, 202329,560,464 $30 $917,107 $800 $(345,423)$572,514 Stock options exercised88,276 — 3,616 — — 3,616 Vesting of restricted stock units41,185 — — — — — Shares held for tax withholdings(14,373)— (2,848)— — (2,848)Issuance of common stock543 — 101 — — 101 Stock-based compensation expense— — 26,322 — — 26,322 Other comprehensive loss— — — (676)— (676)Net loss— — — — (10,005)(10,005)Balance at March 31, 202429,676,095 30 944,298 124 (355,428)589,024 Stock options exercised88,328 — 5,517 — — 5,517 Vesting of restricted stock units21,340 — — — — — Shares held for tax withholdings(10,985)— (1,862)— — (1,862)Issuance of common stock365 — 85 — — 85 Issuance of common stock for employee stock purchase plan30,158 — 3,431 — — 3,431 Stock-based compensation expense— — 32,322 — — 32,322 Other comprehensive loss— — — (239)— (239)Net income— — — — 9,793 9,793 Balance at June 30, 202429,805,301 $30 $983,791 $(115)$(345,635)$638,071 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

8

Inspire Medical Systems, Inc.

Consolidated Statements of Cash Flows (unaudited)

(in thousands)

 Six Months EndedJune 30, 20252024Operating activities  Net loss$(600)$(212)Adjustments to reconcile